KMT2A and acute myeloid leukemia: Pinometostat (EPZ5676), the second generation of these drugs that selectively inhibit H3K79 methylation, has better pharmacokinetic properties than the previous drug and is being studied and tested for the treatment of diseases such as MLL and AML leukemia [138,139].